Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OncoSec forms SAB

This article was originally published in Scrip

Executive Summary

OncoSec Medical, a developer of novel OMS ElectroOncology therapies, has recruited a scientific advisory board consisting of: Dr Richard Heller, director of the Frank Reidy Research Center for Bioelectrics at Old Dominion University; Dr Iacob Mathieson, CEO of Otivio and co-founder of Inovio, where he is now a member of the SAB; and Dr Christian Ottensmeier, professor of experimental cancer research at the University of Southampton. The board will meet bi-annually to review the company's progress in research and clinical development, and will rely on input and expertise from OncoSec's clinical and scientific advisory panel.

You may also be interested in...

Almirall launches Constella in six European markets

Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.

Dermira raises $35m in series B

Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.

Clovis ups public offering to $240m

Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts